Group 1: Clinical Trials and Research - KH631 and KH658 are currently in clinical trials, with safety and efficacy data not yet fully compiled [2] - KH631's clinical data is expected to be disclosed at the 2025 ARVO conference [2] - The company has a diverse R&D system covering traditional Chinese medicine, antibody drugs, gene therapy, and small molecule drugs [10] Group 2: Financial Performance and Projections - In 2024, the company achieved a revenue of CNY 4,452,657,799, a year-on-year increase of 12.51%, and a net profit of CNY 1,191,230,760.93, up 14.02% [14] - For 2025, the company projects a revenue growth of 5%-15% and a net profit growth of 5%-15% compared to 2024 [9] - R&D expenses in 2024 increased by 33.57% to CNY 604,378,287.33 [8] Group 3: Strategic Focus and Market Position - The core competitive advantage lies in strategic layout and continuous innovation across various product lines [3] - The company is focusing on enhancing internal control management and performance assessment to improve overall management efficiency [26] - The company maintains a strong market position in the anti-VEGF sector, with confidence in overcoming competition from global brands [6] Group 4: Product Development and Pipeline - Key products in clinical trials include KH631 for nAMD, KH658 for nAMD, and KH617 for advanced solid tumors [5] - The company is advancing the clinical trials of KH110 for Alzheimer's disease and KH109 for anxiety [15] - The company is actively responding to market competition and regulatory changes, particularly in the traditional Chinese medicine sector [8] Group 5: Future Outlook and Industry Trends - The pharmaceutical industry is viewed as a "perpetual sunrise industry" with significant growth potential [13] - The company is committed to increasing R&D investments to provide high-quality, cost-effective products [22] - The company is exploring international collaboration opportunities to enhance its global market presence [30]

药品名称：KH607 片 剂型：片剂 适应症：产后抑郁症 注册分类：化药 1 类 证券代码：002773 证券简称：康弘药业 公告编号：2025-021 成都康弘药业集团股份有限公司 关于公司收到药物临床试验批准通知书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 近日，成都康弘药业集团股份有限公司（以下简称"公司"）收 到国家药品监督管理局签发的《药物临床试验批准通知书》。现将相 关情况公告如下： 一、药品基本信息 1 / 2 三、对公司的影响 由于药品从研发、临床试验、审评和审批的结果以及时间都具有 一定的不确定性，敬请广大投资者谨慎决策，注意投资风险。 特此公告。 成都康弘药业集团股份有限公司董事会 2025 年 5 月 14 日 2 / 2 受理号：CXHL2500223、CXHL2500224 审批结论：同意开展治疗产后抑郁症的临床试验 二、产品简介 KH607 是我公司自主研发的小分子 γ-氨基丁酸 A 亚型（GABAA） 受体正向变构调节剂，属于化药 1 类创新药，剂型为口服固体制剂片 剂,2023 年已获批同意开展治疗抑郁症的临床试验。 ...

Core Viewpoint - Kanghong Pharmaceutical has experienced a decline in stock price over four consecutive trading days, with a cumulative drop of 8.09% [1] Company Overview - Chengdu Kanghong Pharmaceutical Group Co., Ltd. was established in 1996 and focuses on the research, production, sales, and after-sales service of biological products, traditional Chinese medicine, chemical drugs, and medical devices [1] - The company possesses advanced research and development centers and standardized industrial production bases, with a marketing network that spans the entire country [1] Shareholder Activity - Three funds under Dacheng Fund have entered the top ten shareholders of Kanghong Pharmaceutical, including: - Dacheng Strategy Return Mixed A, which increased its holdings in Q1 of this year - Dacheng Competitive Advantage Mixed A, which also increased its holdings in Q1 - Dacheng Rui Xiang Mixed A, which entered as a new shareholder in Q1 [1] - The performance of these funds in 2023 is as follows: - Dacheng Strategy Return Mixed A: 1.46% return, ranking 2872 out of 4548 - Dacheng Competitive Advantage Mixed A: 4.62% return, ranking 1825 out of 4548 - Dacheng Rui Xiang Mixed A: 2.35% return, ranking 2545 out of 4548 [1] Fund Management - The fund manager for Dacheng Strategy Return Mixed A, Dacheng Competitive Advantage Mixed A, and Dacheng Rui Xiang Mixed A is Xu Yan [5][7] - Xu Yan holds a master's degree in management from Fudan University and has extensive experience in fund management, having worked at Dacheng Fund Management Co., Ltd. since 2007 [6]

本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 成都康弘药业集团股份有限公司（以下简称"康弘药业"、"公 司"）《2024年年度报告》《2024年年度报告摘要》已于2025年4月 26日披露。为使投资者进一步了解公司的财务状况、经营情况及公司 发展规划，公司将于2025年5月15日（星期四）下午15：00至17：00 在全景网举行康弘药业二〇二四年度网上业绩说明会，本次说明会将 采用网络远程方式举行，投资者可登录全景网"投资者关系互动平台" （https://ir.p5w.net）参与本次业绩说明会。 证券代码：002773 证券简称：康弘药业 公告编号：2025-020 成都康弘药业集团股份有限公司 关于举行二〇二四年度网上业绩说明会的公告 出席本次业绩说明会的人员有：公司董事长柯尊洪先生，董事、 总裁柯潇先生，董事、副总裁钟建荣女士、殷劲群先生，独立董事周 德敏先生、邓宏光先生、许楠女士，副总裁、财务总监钟建军先生， 副总裁徐燕华女士，董事会秘书邓康先生。 为充分尊重投资者，提升交流的针对性，现就公司二〇二四年度 业绩网上说明会提前向投资者公开征集问题，广 ...

近日，公司已向中国证券登记结算有限责任公司深圳分公司提交 注销上述股票期权的申请，截至本公告披露日，经中国证券登记结算 有限责任公司深圳分公司审核确认，公司已完成上述 198,750 份股票 期权的注销业务。前述注销 2021 年股票期权激励计划部分股票期权 事项符合《上市公司股权激励管理办法》及公司《2021 年股票期权激 证券代码：002773 证券简称：康弘药业 公告编号：2025-019 成都康弘药业集团股份有限公司 关于2021年股票期权激励计划部分股票期权 注销完成的公告 | 本公司及董事会全体成员保证信息披露内容的真实、准确和完 | | --- | | 整，没有虚假记载、误导性陈述或重大遗漏。 | 成都康弘药业集团股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日召开第八届董事会第十次会议和第八届监事会第十次会议， 审议通过了《关于注销 2021 年股票期权激励计划部分股票期权的议 案》。根据公司《2021 年股票期权激励计划（草案）》的相关规定，由 于 2021 年股票期权激励计划首次授予部分的 13 名激励对象离职，董 事会根据公司二〇二一年第一次临时股东大会的授权，决定注销 ...

Group 1: Shanghai Jahwa - Shanghai Jahwa is confident about achieving high double-digit GMV growth for its core brands during the 618 shopping festival [1] - The employee stock ownership plan aims to enhance competitiveness, reduce turnover, and foster a sense of ownership among employees [1] - The company has made strategic adjustments in the past six months, including organizational design, talent development, and cultural initiatives [1] - E-commerce strategies include inventory optimization, pricing adjustments, organizational restructuring, and product iteration [1] - The company targets double-digit revenue growth this year and aims to turn profits around [1] - Long-term profit recovery is expected to follow a 1-2 year revenue growth, 2-3 year profit improvement, and 3-5 year profit margin targets [1] Group 2: Zhuoyi Information - Zhuoyi Information has approximately 7,000 active users for its SnapDevelop platform and plans to release a paid commercial version [2] - EazyDevelop, which focuses on rapid development using AI technology, will have a free trial version available after development [2] - The company has made breakthroughs in RISC-V firmware and is collaborating with major firms like Huawei and Lenovo [2] Group 3: Chipbond Technology - Chipbond Technology has made progress in advanced packaging, with its WLP2000 equipment entering mass production preparation after client validation [3] - The company benefits from advantageous direct-write lithography technology and has seen a 22.31% year-on-year increase in revenue and a 30.45% increase in net profit in Q1 [3] - The company expects overseas orders to account for nearly 20% by 2024, indicating strong international market competitiveness [3] Group 4: Kanghong Pharmaceutical - Kanghong Pharmaceutical's KPB-101 has established a leading position in China's ophthalmic anti-VEGF market and aims for further achievements [4] - The company focuses on diverse research and development in ophthalmology, neurology, and oncology, with a strong emphasis on innovative drug sales [4] - The company anticipates a revenue and net profit growth of 5%-15% year-on-year by 2025, with specific products expected to see significant sales growth [4]

Market Position and Growth Potential - Kanghong Pharmaceutical has established a leading position in the Chinese ophthalmic anti-VEGF market, competing against three major global brands [2] - The company has successfully navigated market challenges over the past decade, demonstrating confidence in continuing to outperform international competitors [2] - The incidence rates of the five major indications for anti-VEGF products are stable, suggesting that Kanghong's growth will align with the overall market trend [2] Research and Development Strategy - The company focuses on key therapeutic areas: ophthalmology, psychiatry/neuroscience, and oncology, with a diversified R&D system covering traditional Chinese medicine, antibody drugs, gene therapy (AAV), and small molecule drugs [3] - Kanghong is advancing multiple innovative projects, including the "Shu Gan Jie Yu Capsule" for anxiety disorders, which is currently in phase III clinical trials [3][7] - The company plans to disclose clinical data for its gene therapy products through international academic journals and conferences [4] Financial Outlook - For 2025, Kanghong anticipates a revenue growth of 5%-15% compared to 2024, with a similar net profit growth forecast [7] - The "Shu Gan Jie Yu Capsule" is expected to see double-digit growth in 2024, outpacing the overall antidepressant market [7] Competitive Landscape and Policy Impact - The competitive landscape for anti-VEGF products has intensified, with four innovative drugs and two biosimilars entering the market following successful negotiations with national health insurance [5] - Kanghong is adapting to national procurement policies, with a significant portion of its chemical drugs selected for national procurement [4] Talent and Collaboration - The company emphasizes talent acquisition and development to support its R&D needs, particularly in gene therapy and advanced drug delivery systems [6] - External collaborations are viewed as a core strategy for long-term value growth, focusing on complementary technologies and commercial synergies [6]

Core Insights - The article highlights the rapid growth of the ophthalmic drug market in China, with Kanghong Pharmaceutical's product "Langmu" breaking the monopoly of imported drugs and achieving significant sales [1][4][5] - Kanghong Pharmaceutical has established itself as a leader in the innovative drug sector, focusing on ophthalmology, mental health, and oncology, with a strong emphasis on innovation and quality [3][7][12] Company Performance - In 2024, Kanghong Pharmaceutical's biopharmaceutical business revenue reached 2.343 billion yuan, a year-on-year increase of 20.98%, accounting for 52.61% of total revenue [1] - The sales of Kanghong's product, Kangbaxip, reached 500 million yuan in 2023, capturing 36% of the market share [1] - The company has maintained a consistent growth trajectory for Kangbaxip over the past 11 years, with over 2.5 million injections administered [1][5] Market Dynamics - The global ophthalmic drug market is projected to reach $83.477 billion by 2031, with a compound annual growth rate (CAGR) of 9.1% from 2024 to 2031 [3] - China has over 40 million patients with retinal diseases, with more than 3 million new patients added annually, indicating a significant market opportunity [4][8] Innovation and R&D - Kanghong Pharmaceutical has a comprehensive R&D strategy, with 21 marketed drugs, 10 of which are exclusive and 17 included in the national medical insurance directory [3][12] - The company is actively developing gene therapy and antibody drugs, with two ophthalmic products in clinical trials aimed at reducing injection frequency for patients [9][10] Production Capacity - Kanghong is investing in building production capabilities for gene therapy drugs, establishing a full-chain capability from R&D to commercialization [12][13] - The company has constructed GMP-compliant production bases in Beijing and Chengdu, enhancing its manufacturing capabilities for biopharmaceuticals [13]

成都康弘药业集团股份有限公司 二、独立董事年度履职概况 1、出席股东大会和董事会情况 | | | | 出席董事会会议情况 | | | 出席股东大会会议情况 | | --- | --- | --- | --- | --- | --- | --- | | 独立董事 | 任职期间 | 现场出席 | 通讯出席 | | 任职期间 | 实际出席 | | 姓名 | 报告期内 | | | 缺席次数 | 报告期内 | | | | | 次数 | 次数 | | | 次数 | | | 会议次数 | | | | 会议次数 | | | 许楠 | 5 | 2 | 3 | 0 | 1 | 1 | 报告期内，本人积极参加公司召开的所有董事会、股东大会，本 二〇二四年度独立董事述职报告 二〇二四年度，本人作为成都康弘药业集团股份有限公司（以下 简称"公司"）的独立董事，严格按照《中华人民共和国公司法》《上 市公司治理准则》《上市公司独立董事管理办法》等有关法律法规， 以及公司《独立董事制度》《公司章程》的规定和要求开展工作，忠 实履行职责，积极出席相关会议，认真审议董事会各项议案，充分发 挥了独立董事的作用，较好地维护了社会公众股股东的合法权益 ...

成都康弘药业集团股份有限公司 二〇二四年度独立董事述职报告 二〇二四年度，本人作为成都康弘药业集团股份有限公司（以下 简称"公司"）的独立董事，严格按照《中华人民共和国公司法》《上 市公司治理准则》《上市公司独立董事管理办法》等有关法律法规， 以及公司《独立董事制度》《公司章程》的规定和要求开展工作，忠 实履行职责，积极出席相关会议，认真审议董事会各项议案，充分发 挥了独立董事的作用，较好地维护了社会公众股股东的合法权益。现 将二〇二四年的工作情况简要汇报如下： 一、独立董事的基本情况 邓宏光，1977 年 10 月出生，中国国籍，无境外居留权，法学博 士、博士后，西南政法大学民商法学院教授、博士生导师，现担任西 南政法大学知识产权研究中心副主任，重庆知识产权保护协同创新中 心副主任，中国知识产权法学研究会理事，公司独立董事。荣获商务 部海外知识产权维权专家称号、第二届全国知识产权领军人才等。 报告期内，本人作为公司独立董事任职符合《上市公司独立董事 管理办法》第六条规定的独立性要求，不存在影响独立性的情况。 二、独立董事年度履职概况 1、出席股东大会和董事会情况 | | | 出席董事会会议情况 | | | ...